Compare Tango Therapeutics Inc. (TNGX) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Toro Company (The) Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.30B). The key difference: Toro Company (The) Common Stock is far larger — about 2.5× Tango Therapeutics Inc.'s market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Toro Company (The) Common Stock for 0 Days on average.
| TNGX | TTC | |
|---|---|---|
Market Cap | $3.74B | $9.30B |
Volume | 3,438,781 | 420,909 |
Sector | Health | Industrials |
52-Week High | $32.90 | $101.76 |
52-Week Low | $7.50 | $67.99 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.76B | $10.20B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
